Top

Published in:

01-08-2014 | Original Article

Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis

Authors: Masanori Kobayashi, Shigetaka Shimodaira, Kazuhiro Nagai, Masahiro Ogasawara, Hidenori Takahashi, Hirofumi Abe, Mitsugu Tanii, Masato Okamoto, Sun-ichi Tsujitani, Seiichi Yusa, Takefumi Ishidao, Junji Kishimoto, Yuta Shibamoto, Masaki Nagaya, Yoshikazu Yonemitsu, The DC Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT)

Published in: Cancer Immunology, Immunotherapy | Issue 8/2014

Abstract

Objective

Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimens.

Methods

Of 354 patients who met the inclusion criteria, 255 patients who received standard chemotherapy combined with peptide-pulsed DC vaccines were analyzed.

Results

The mean survival time from diagnosis was 16.5 months (95 % CI 14.4–18.5) and that from the first vaccination was 9.9 months (95 % CI 8.0–12.9). Known prognostic baseline factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, liver metastasis, and the prognostic nutrition index, were also representative. Importantly, we found that erythema reaction after vaccination was an independent and treatment-related prognostic factor for better survival and that OK-432 might be a good adjuvant enhancing the antitumor immunity during DC vaccination.

Conclusions

This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of an add-on DC vaccine in patients with advanced pancreatic cancer who are undergoing chemotherapy. These findings need to be addressed in well-controlled prospective randomized trials.

Available only for authorised users

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Wada K, Takaori K, Traverso LW, Hruban RH, Furukawa T, Brentnall TA et al (2013) Clinical importance of familial pancreatic cancer registry in Japan: a report from kick-off meeting at international symposium on pancreas cancer 2012. J Hepatobiliary Pancreat Sci 20:557–566CrossRef

Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731PubMedCrossRef

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: gEST Study. J Clin Oncol 31:1640–1648PubMedCrossRef

Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T et al (1998) Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13:693–698PubMed

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252PubMedCrossRef

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58PubMedCrossRef

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedCrossRef

10.

Pecher G, Häring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669–673PubMedCrossRef

11.

Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K et al (2008) Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 28:379–387PubMed

12.

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G et al (2011) hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 60:809–818PubMedCentralPubMedCrossRef

13.

Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A et al (2011) Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother 60:1097–1107PubMedCrossRef

14.

Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D et al (2011) A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med 12:173–180PubMedCrossRef

15.

Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K et al (2012) Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 41:195–205PubMedCrossRef

16.

Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A et al (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70:3052–3061PubMedCrossRef

17.

Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA et al (2007) Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56:1275–1282PubMedCentralPubMedCrossRef

18.

Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T et al (2003) Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13:521–530PubMedCrossRef

19.

Kuwabara K, Nishishita T, Morishita M, Oyaizu N, Yamashita S, Kanematsu T et al (2007) Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid 17:53–58PubMedCrossRef

20.

Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT) et al (2013) Impact of dendritic cell vaccines pulsed with Wilms’ tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur J Cancer 49:852–859PubMedCrossRef

21.

Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A et al (2013) DC-vaccine study group at the Japan society of innovative cell therapy (J-SICT) dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 17:1609–1617PubMedCrossRef

22.

Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N et al (2004) Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95:583–587PubMedCrossRef

23.

Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR (1994) Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 57:198–203PubMedCrossRef

24.

Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H et al (2003) Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95:316–326PubMedCrossRef

25.

Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU et al (2004) Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64:5461–5470PubMedCrossRef

26.

Pinato DJ, North BV, Sharma R (2012) A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer 106:1439–1445PubMedCentralPubMedCrossRef

27.

Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268–274PubMedCrossRef

28.

Park S, Chung MJ, Park JY, Chung JB, Bang S, Park SW et al (2013) Phase II trial of erlotinib plus gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer and prognostic factors for chemotherapeutic response. Gut Liver 7:611–615PubMedCentralPubMedCrossRef

29.

Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ et al (2012) Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 48:1434–1442PubMedCrossRef

30.

Yi JH, Lee J, Park SH, Lee KT, Lee JK, Lee KH et al (2011) A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 80:175–180PubMedCrossRef

31.

Inal A, Ciltas A, Yildiz R, Berk V, Kos FT, Dane F et al (2012) Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study. Asian Pac J Cancer Prev 13:1841–1844PubMedCrossRef

32.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397PubMedCentralPubMedCrossRef

33.

de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779–5787PubMedCrossRef

34.

Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C et al (2004) Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53:125–134PubMedCrossRef

35.

Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takehara A et al (2014) Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37:105–114PubMedCrossRef

36.

Sugimachi K, Maehara Y, Akazawa K, Kondo Y, Kunii Y, Kitamura M et al (1994) Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study. Cancer Chemother Pharmacol 33:366–370PubMedCrossRef

Title: Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
Authors: Masanori Kobayashi
Shigetaka Shimodaira
Kazuhiro Nagai
Masahiro Ogasawara
Hidenori Takahashi
Hirofumi Abe
Mitsugu Tanii
Masato Okamoto
Sun-ichi Tsujitani
Seiichi Yusa
Takefumi Ishidao
Junji Kishimoto
Yuta Shibamoto
Masaki Nagaya
Yoshikazu Yonemitsu
The DC Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT)
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 8/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-014-1554-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation

Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies

Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer